...
首页> 外文期刊>The international journal of neuropsychopharmacology >A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia
【24h】

A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia

机译:对传统日本药(yampkansan)yokukansan治疗痴呆症的行为和心理症状的随机交叉研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The effectiveness and safety of yokukansan (TJ-54), a traditional Japanese medicine (kampo) for the treatment of the behavioural and psychological symptoms of dementia (BPSD), were evaluated in 106 patients diagnosed as having Alzheimer's disease (AD) (including mixed-type dementia) or dementia with Lewy bodies. Patients were randomly assigned to group A (TJ-54 treatment in period I and no treatment in period II; each period lasting 4 wk) or group B (no treatment in period I and TJ-54 treatment in period II). BPSD and cognitive functions were evaluated using the Neuropsychiatric Inventory (NPI) and the Mini-Mental State Examination (MMSE), respectively. Activities of daily living (ADL) were evaluated using Instrumental Activities of Daily Living (IADL) in outpatients and the Barthel Index in in-patients. For the safety evaluation, adverse events were investigated. Significant improvements in mean total NPI score associated with TJ-54 treatment were observed in both periods (Wilcoxon test, p=0.040 in period I and p=0.048 in period II). The mean NPI scores significantly improved during TJ-54 treatment in groups A and B (p=0.002 and p=0.007, respectively) but not during periods of no treatment. Among the NPI subscales, significant improvements were observed in delusions, hallucinations, agitation/aggression, depression, anxiety, and irritability/lability. The effects of TJ-54 persisted for 1 month without any psychological withdrawal symptoms in group A. TJ-54 did not show any effect on either cognitive function or ADL. No serious adverse reactions were observed. The present study suggests that TJ-54 is an effective and well-tolerated treatment for patients with BPSD.
机译:对106名被诊断患有阿尔茨海默氏病(AD)(包括混合性痴呆)的行为和心理症状(yk)的传统日药(kampo)yokukansan(TJ-54)的有效性和安全性进行了评估型痴呆)或路易体痴呆。患者被随机分为A组(I期为TJ-54治疗,II期为无治疗;每个周期持续4周)或B组(I期为无治疗,II期为TJ-54治疗)。分别使用神经精神病学量表(NPI)和小精神状态检查(MMSE)评估BPSD和认知功能。使用门诊患者的日常仪器活动(IADL)和住院患者的Barthel指数评估了日常生活活动(ADL)。为了进行安全性评估,调查了不良事件。在两个时期中均观察到与TJ-54治疗相关的平均总NPI得分显着提高(Wilcoxon检验,I期p = 0.040,II期p = 0.048)。 A组和B组在TJ-54治疗期间平均NPI得分显着提高(分别为p = 0.002和p​​ = 0.007),但未治疗期间则没有。在NPI子量表中,观察到妄想,幻觉,躁动/攻击,抑郁,焦虑和易怒/不稳定性的显着改善。 A组中TJ-54的作用持续了1个月,没有任何心理戒断症状。TJ-54对认知功能或ADL均未显示任何作用。没有观察到严重的不良反应。本研究表明,TJ-54对BPSD患者是一种有效且耐受良好的治疗方法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号